Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Abroad (travel likely)RecruitingPHASE2
Conditions
Grade 1 Follicular Lymphoma · Grade 2 Follicular Lymphoma · Grade 3a Follicular Lymphoma · Indolent Non-Hodgkin Lymphoma · Lymphoplasmacytic Lymphoma · Lymphoproliferative Disorder · Mantle Cell Lymphoma · Marginal Zone Lymphoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Contact: Principal Investigator (Jonathon Cohen, MD,MS)
Study leads
Jonathon B Cohen, MD, MS
Principal Investigator
Emory University